Advertisement

Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders

  • Ryuji SakakibaraEmail author
Review

Abstract

Purpose

Multiple sclerosis (MS), neuromyelitis optica (NMO), and related disorders are major immune-mediated central nervous system diseases affecting the spinal cord. We reviewed the occurrence of neurogenic lower urinary tract dysfunction (NLUTD) in these categories of diseases.

Methods

We systematically reviewed the literature regarding bladder dysfunction in MS, NMO spectrum disorder (NMOSD), and related disorders (acute disseminated encephalomyelitis, acute immune-mediated myelopathy, and meningitis-retention syndrome).

Results

The literature, although somewhat limited for diseases other than MS, suggests that bladder dysfunction is not uncommon in these diseases, presumably reflecting lesions in the spinal descending and ascending pathways. The pattern of bladder dysfunction is a combination of overactive bladder and large post-void residuals/urinary retention. Post-void residual is measured by portable ultrasound devices.

Conclusions

Because of the complexity of bladder behavior, careful consideration of bladder management is necessary in MS, NMO, and related disorders: e.g., antimuscarinics, etc., for overactive bladder and clean, intermittent self-catheterization for urinary retention. These management practices should help improve patients’ quality of life.

Keywords

Multiple sclerosis Neuromyelitis optica Spinal cord Overactive bladder Urinary retention 

Notes

Compliance with ethical standards

Conflict of interest

We have no conflict of interest.

Ethical approval

This article conforms to the ethical standards of the declaration of Helsinki.

References

  1. 1.
    Abboud H, Hill E, Siddiqui J, Serra A, Walter B (2017) Neuromodulation in multiple sclerosis. Mult Scler 23:1663–1676CrossRefPubMedGoogle Scholar
  2. 2.
    Adamec I, Habek M (2013) Autonomic dysfunction in multiple sclerosis. Clin Neurol Neurosurg 115(Suppl 1):S73–S78CrossRefPubMedGoogle Scholar
  3. 3.
    Altuntas CZ, Daneshgari F, Liu G, Fabiyi A, Kavran M, Johnson JM, Gulen MF, Jaini R, Li X, Frenkl TL, Tuohy VK (2008) Bladder dysfunction in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 203:58–63CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Amarenco G, Raibaut P, Hubeaux K, Jousse M, Sheikh Ismaël S, Lapeyre E (2013) Autonomic nervous system alteration in multiple sclerosis patients with urinary symptoms. Clinical, urodynamic and cardiovascular study. Prog Urol 23:1505–1510CrossRefPubMedGoogle Scholar
  5. 5.
    Basoulis D, Mylon M, Toskas P, Tsilingiris D, Fytili C (2015) Meningitis-retention syndrome. Int Neurourol J 19:207–209CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bradl M, Reindl M, Lassmann H (2018) Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Curr Opin Neurol 31:325–333PubMedPubMedCentralGoogle Scholar
  7. 7.
    Burla MJ, Benjamin J (2016) Pediatric urinary retention in the emergency department: a concerning symptom with etiology outside the bladder. J Emerg Med 50:e53–e56CrossRefPubMedGoogle Scholar
  8. 8.
    Canbaz Kabay S, Kabay S, Mestan E, Cetiner M, Ayas S, Sevim M, Ozden H, Karaman HO (2017) Long term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients: 12 months results. Neurourol Urodyn 36:104–110CrossRefPubMedGoogle Scholar
  9. 9.
    Canon S, Shera A, Phan NM, Lapicz L, Scheidweiler T, Batchelor L, Swearingen C (2015) Autonomic dysreflexia during urodynamics in children and adolescents with spinal cord injury or severe neurologic disease. J Pediatr Urol 11:32 e1–32 e4CrossRefGoogle Scholar
  10. 10.
    Cartier RL, Hansen BF (2014) Meningitis-retention syndrome. Rep One Case Rev Med Chile 142:1607–1611CrossRefGoogle Scholar
  11. 11.
    Castel-Lacanal E, Gamé X, Clanet M, Gasq D, De Boissezon X, Guillotreau J, Bourg V, Viala F, Rischmann P, Marque P (2015) Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients. Neurourol Urodyn 34:32–36CrossRefPubMedGoogle Scholar
  12. 12.
    Charil A, Zijdenbos AP, Taylor J, Boelman C, Worsley KJ, Evans AC, Dagher A (2003) Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets. Neuroimage 19:532–544CrossRefPubMedGoogle Scholar
  13. 13.
    de Carvalho FL, Gomes CM, Apostolos-Pereira SL, Bessa J Jr, Pinheiro M, Marchiori PE, Bruschini H, Srougi M, Callegaro D (2016) Voiding dysfunction in patients with neuromyelitis optica spectrum disorders. Neurourol Urodyn 35:39–43CrossRefPubMedGoogle Scholar
  14. 14.
    De Ridder D, Der Van, Aa F, Debruyne J, D’hooghe MB, Dubois B, Guillaume D, Heerings M, Ilsbroukx S, Medaer R, Nagels G, Seeldrayers P, Van Landegem W, Willekens B, Zicot AF (2013) Consensus guidelines on the neurologist’s role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis. Clin Neurol Neurosurg 115:2033–2040CrossRefPubMedGoogle Scholar
  15. 15.
    De Santis G, Zenzola A, Carbone A, Ciardo G (2015) Neurogenic sphincters dysfunction as unusual clinical picture of ADEM. Acta Neurol Belg 115:787–788CrossRefPubMedGoogle Scholar
  16. 16.
    de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915–928CrossRefPubMedGoogle Scholar
  17. 17.
    Dimitrijevic N, Bogicevic D, Dimitrijevic A, Nikolic D (2012) Early presentation of neuromyelitis optica. Indian Pediatr 49:924–925CrossRefPubMedGoogle Scholar
  18. 18.
    Dos Passos GR, Oliveira LM, da Costa BK, Apostolos-Pereira SL, Callegaro D, Fujihara K, Sato DK (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Flanagan EP (2016) Autoimmune myelopathies. Handb Clin Neurol 133:327–351CrossRefPubMedGoogle Scholar
  20. 20.
    Fowler CJ (2010) The effectiveness of bladder rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 81:944CrossRefPubMedGoogle Scholar
  21. 21.
    Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M (2009) A UK consensus on th management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry 80:470–477PubMedGoogle Scholar
  22. 22.
    Franken J, Gevaert T, Uvin P, Wauterickx K, Boeve AC, Rietjens R, Boudes M, Hendriks JJ, Hellings N, Voets T, De Ridder D (2016) Urodynamic changes in mice with experimental autoimmune encephalomyelitis correlate with neurological impairment. Neurourol Urodyn 35:450–456CrossRefPubMedGoogle Scholar
  23. 23.
    Fujiki F, Tsuboi Y, Hori T, Yamada T (2008) Aseptic meningitis as initial presentation of acute disseminated encephalomyelitis. J Neurol Sci 272(1–2):129–131CrossRefPubMedGoogle Scholar
  24. 24.
    Furlana JC (2018) Autonomic dysreflexia following acute myelitis due to neuromyelitis optica. Mult Scler Relat Disord 23:1–3CrossRefGoogle Scholar
  25. 25.
    Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, Dickinson T, Payne CK, Drake MJ, Haylen BT (2018) An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 37:1152–1161CrossRefPubMedGoogle Scholar
  26. 26.
    Ghezzi A, Carone R, Del Popolo G, Amato MP, Bertolotto A, Comola M, Del Carro U, Di Benedetto P, Giannantoni A, Lopes de Carvalho ML, Montanari E, Patti F, Protti A, Rasia S, Salonia A, Scandellari C, Sperli F, Spinelli M, Solaro C, Uccelli A, Zaffaroni M, Zipoli V, Multiple Sclerosis Study Group, Italian Society of Neurology (2011) Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurol Sci 32:1223–1231CrossRefPubMedGoogle Scholar
  27. 27.
    Gliga LA, Lavelle RS, Christie AL, Coskun B, Greenberg BM, Carmel ME, Lemack GE (2017) Urodynamics findings in transverse myelitis patients with lower urinary tract symptoms: results from a tertiary referral urodynamic center. Neurourol Urodyn 36:360–363CrossRefPubMedGoogle Scholar
  28. 28.
    Gupta A, Kumar SN, Taly AB (2017) Urodynamic profile in acute transverse myelitis patients: its correlation with neurological outcome. J Neurosci Rural Pract 8:44–48CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hiraga A, Kuwabara S (2018) Meningitis-retention syndrome: clinical features, frequency and prognosis. J Neurol Sci 390:261–264CrossRefPubMedGoogle Scholar
  30. 30.
    Hiraga A, Sakakibara R, Mori M, Suzuki A, Hattori T (2005) Bilateral lesion in the lateral columns and complete urinary retention: association with the spinal cord descending pathway for micturition. Neurourol Urodyn 24:398–399CrossRefPubMedGoogle Scholar
  31. 31.
    Hiraga A, Sakakibara R, Mori M, Yamanaka Y, Ito S, Hattori T (2006) Urinary retention can be the sole initial manifestation of acute myelitis. J Neurol Sci 251:110–112CrossRefPubMedGoogle Scholar
  32. 32.
    Hiraga A, Takatsuna Y, Sakakibara R, Kamitsukasa I, Minamide M, Kuwabara S (2014) Vogt–Koyanagi–Harada disease with meningitis-retention syndrome and increased CSF adenosine deaminase levels. Clin Neurol Neurosurg 127:42–43CrossRefPubMedGoogle Scholar
  33. 33.
    Hollingsworth JM, Rogers MA, Krein SL, Hickner A, Kuhn L, Cheng A, Chang R, Saint S (2013) Determining the noninfectious complications of indwelling urethral catheters: a systematic review and meta-analysis. Ann Intern Med 159:401–410CrossRefPubMedGoogle Scholar
  34. 34.
    Ishii G, Hata K, Aoki S, Suzuki M, Kimura T, Egawa S (2016) Meningitis-retention syndrome. Case Rep Urol Case Rep 6:42–44PubMedGoogle Scholar
  35. 35.
    Jayakrishnan MP, Krishnakumar P, Gauthamen R, Sabitha S, Devarajan E (2012) Autonomic dysreflexia in acute disseminated encephalomyelitis. Pediatr Neurol 47:309–311CrossRefPubMedGoogle Scholar
  36. 36.
    Jin Z, Ding Y, Xue R, Jia Z, Huang Z, Ding Y, Gu C, Yang J (2017) Involvement of interstitial cells of Cajal in bladder dysfunction in mice with experimental autoimmune encephalomyelitis. Int Urol Nephrol 49:1353–1359CrossRefPubMedGoogle Scholar
  37. 37.
    Kanesaka T, Sakakibara R, Ito S, Ito T, Odaka T, Yamaguchi T, Uchiyama T, Liu Z, Yamamoto T, Hattori T (2006) Intestinal pseudo-obstruction in acute myelitis. Intern Med 45:35–36CrossRefPubMedGoogle Scholar
  38. 38.
    Kennedy F, Elsberg CA, Lambert CI (1913) A peculiar undescribed disease of the nerves of the cauda equina. Am J Med Sci 147:645–667CrossRefGoogle Scholar
  39. 39.
    Kim T, Whang J, Lee S, Choi J, Park S, Lee J (2010) Acute urinary retention due to aseptic meningitis: meningitis-retention syndrome. Int Neurourol J 14:122–124CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kim SM, Waters P, Woodhall M, Yang JW, Yang H, Kim JE, Sung JJ, Park KS, Lee KW (2014) Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status. BMC Neurol 14:93CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Koutsis G, Evangelopoulos ME, Sfagos C, Markianos M (2016) Neurochemical and neuroendocrine correlates of overactive bladder at first demyelinating episode. Neurourol Urodyn 35:955–958CrossRefPubMedGoogle Scholar
  42. 42.
    Krishna A, Devulapally P, Ghobrial I (2012) Meningitis retention syndrome. J Community Hosp Intern Med Perspect 2:15761.  https://doi.org/10.3402/jchimp.v2i1.15761 CrossRefGoogle Scholar
  43. 43.
    Legrand G, Rouprêt M, Comperat E, Even-Schneider A, Denys P, Chartier-Kastler E (2011) Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology 78:937–941CrossRefPubMedGoogle Scholar
  44. 44.
    Lifson JD, Oyasu R, Dreyer N, Carone FA, Williams RM (1983) Acute hemorrhagic obstructive uropathy as a complication of experimental autoimmune encephalomyelitis. Arch Pathol Lab Med 107:600–602PubMedGoogle Scholar
  45. 45.
    Mankongpaisarnrung C, Laengvejkal P, Argueta E, Limsuwat C, Sutamtewagul G, Nugent K (2013) Meningitis-retention syndrome as a presentation of West Nile virus meningitis. Case Rep Med 2013:984345.  https://doi.org/10.1155/2013/984345 CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mutch K, Zhao S, Hamid S, Methley A, Elsone L, Singh G, Young C, Emmanuel A, Panicker J, Jacob A (2015) Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 4:614–618CrossRefPubMedGoogle Scholar
  47. 47.
    Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (2018) The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep 18(2):8CrossRefPubMedGoogle Scholar
  48. 48.
    Ochi H, Fujihara K (2016) Demyelinating diseases in Asia. Curr Opin Neurol 29:222–228CrossRefPubMedGoogle Scholar
  49. 49.
    Panicker JN, Fowler CJ (2015) Lower urinary tract dysfunction in patients with multiple sclerosis. Handb Clin Neurol 130:371–381CrossRefPubMedGoogle Scholar
  50. 50.
    Panicker JN, Nagaraja D, Kovoor JM, Nair KP, Subbakrishna DK (2009) Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Mult Scler 15:1118–1122CrossRefPubMedGoogle Scholar
  51. 51.
    Phé V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13:275–288CrossRefPubMedGoogle Scholar
  52. 52.
    Podnar S, Vodušek DB (2014) Place of perineal electrophysiologic testing in multiple sclerosis patients. Ann Phys Rehabil Med 57:288–296CrossRefPubMedGoogle Scholar
  53. 53.
    Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, Belman AL (2016) Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology 87(9 Suppl 2):S38–S45CrossRefPubMedGoogle Scholar
  54. 54.
    Pozzilli C, Grasso MG, Bastianello S, Anzini A, Salvetti M, Bozzao L, Von Heland M, Fieschi C (1992) Structural brain correlates of neurologic abnormalities in multiple sclerosis. Eur Neurol 32:228–230CrossRefPubMedGoogle Scholar
  55. 55.
    Sakakibara R, Hattori T, Yasuda K, Yamanishi T (1996) Micturitional disturbance in acute disseminated encephalomyelitis (ADEM). J Auton Nerv Syst 60:200–205CrossRefPubMedGoogle Scholar
  56. 56.
    Sakakibara R, Hattori T, Yasuda K, Yamanishi T (1996) Micturition disturbance in acute transverse myelitis. Spinal Cord 34:481–485CrossRefPubMedGoogle Scholar
  57. 57.
    Sakakibara R, Mori M, Fukutake T, Kita K, Hattori T (1997) Orthostatic hypotension in a case with multiple sclerosis. Clin Auton Res 7:163–165CrossRefPubMedGoogle Scholar
  58. 58.
    Sakakibara R, Uchiyama T, Liu Z, Yamamoto T, Ito T, Uzawa A et al (2005) Meningitis-retention syndrome; an unrecognized clinical condition. J Neurol 252:1495–1499CrossRefPubMedGoogle Scholar
  59. 59.
    Sakakibara R, Kishi M, Tsuyusaki Y, Tateno A, Tateno F, Uchiyama T, Yamamoto T, Yamanishi T, Yano M (2013) “Meningitis-retention syndrome”: a review. Neurourol Urodyn 32:19–23CrossRefPubMedGoogle Scholar
  60. 60.
    Sakakibara R, Ito T, Yamamoto T, Uchiyama T, Yamanishi T, Kishi M, Tsuyusaki Y, Tateno F, Katsuragawa S, Kuroki N (2013) Depression, anxiety and the bladder. Low Urin Tract Symptoms 5:109–120CrossRefPubMedGoogle Scholar
  61. 61.
    Schurch B, Carda S (2014) Onabotulinumtoxin A and multiple sclerosis. Ann Phys Rehabil Med 57:302–314CrossRefPubMedGoogle Scholar
  62. 62.
    Sheremata W, Tornes L (2013) Multiple sclerosis and the spinal cord. Neurol Clin 31:55–77CrossRefPubMedGoogle Scholar
  63. 63.
    Tamam Y, Özdemir HH, Gedik A, Tamam C, Nazlıkul H (2017) Efficacy of peripheral lidocaine application (neural therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Neurourol Urodyn 36:1832–1838CrossRefPubMedGoogle Scholar
  64. 64.
    Tateno F, Sakakibara R, Sugiyama M, Takahashi O, Kishi M, Ogawa E et al (2011) Meningitis-retention syndrome: first case of urodynamic follow-up. Intern Med 50:1329–1332CrossRefPubMedGoogle Scholar
  65. 65.
    Ukkonen M, Elovaara I, Dastidar P, Tammela TL (2004) Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. Acta Neurol Scand 109:100–105CrossRefPubMedGoogle Scholar
  66. 66.
    Vignes JR, Deloire MS, Petry KG, Nagy F (2007) Characterization and restoration of altered inhibitory and excitatory control of micturition reflex in experimental autoimmune encephalomyelitis in rats. J Physiol 578(Pt 2):439–450CrossRefPubMedGoogle Scholar
  67. 67.
    Vignes JR, Deloire M, Petry K (2009) Animal models of sacral neuromodulation for detrusor overactivity. Neurourol Urodyn 28:8–12CrossRefPubMedGoogle Scholar
  68. 68.
    Weissbart SJ, Pechersky D, Malykhina A, Bavaria T, Parrillo L, Arya LA, Bilello M, Wein AJ, Smith AL (2017) The impact of pontine disease on lower urinary tract symptoms in patients with multiple sclerosis. Neurourol Urodyn 36:453–456CrossRefPubMedGoogle Scholar
  69. 69.
    Wingerchuk DM (2018) Immune-mediated myelopathies. Continuum Minneap Minn 24(2 Spinal Cord Disorders):497–522PubMedGoogle Scholar
  70. 70.
    Wingerchuk DM, Weinshenker BG (2014) Neuromyelitis optica (Devic’s syndrome). Handb Clin Neurol 122:581–599CrossRefPubMedGoogle Scholar
  71. 71.
    Yamamoto T, Masahiro Mori M, Uzawa A, Uchiyama T, Sakakibara R, Yanagisawa M, Kuwabara S (2015) Urinary symptoms and neurological disabilities are differentially correlated between multiple sclerosis and neuromyelitis optica. Clin Exp Neuroimmunol 7(1):52–58.  https://doi.org/10.1111/cen3.12279 CrossRefGoogle Scholar
  72. 72.
    Zachariou A, Filiponi M, Baltogiannis D, Giannakis J, Dimitriadis F, Tsounapi P, Takenaka A, Sofikitis N (2017) Effective treatment of neurogenic detrusor overactivity in multiple sclerosis patients using desmopressin and mirabegron. Can J Urol 24:9107–9113PubMedGoogle Scholar
  73. 73.
    Zurawski J, Stankiewicz J (2018) Multiple sclerosis re-examined: essential and emerging clinical concepts. Am J Med 131:464–472CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Neurology, Internal Medicine, Sakura Medical CenterToho UniversitySakuraJapan

Personalised recommendations